penicillamine has been researched along with Multiple Sclerosis in 8 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months." | 9.04 | Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study. ( Cendrowski, W; Czlonkowska, A, 1976) |
| "A pilot study of the effect of D-penicillamine in multiple sclerosis (MS) was undertaken because of D-penicillamine's activity against RNA neurotropic viruses, because it is effective against the auto-immune disease, rheumatoid arthritis, and because both viruses and autoimmunity have been implicated in multiple sclerosis." | 7.66 | Pilot study of d-penicillamine, vitamins and minerals in multiple sclerosis. ( Alba, A; Berger, AR; Rudez, A; Seelig, MS; Tarlau, M, 1978) |
| "It has been suggested that lead may be a cause of multiple sclerosis, but confirmation of this hypothesis is difficult to obtain as lead is so widely present both in the environment and in many human tissues." | 7.65 | Lead and multiple sclerosis. ( , 1976) |
| "Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months." | 5.04 | Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study. ( Cendrowski, W; Czlonkowska, A, 1976) |
| "A pilot study of the effect of D-penicillamine in multiple sclerosis (MS) was undertaken because of D-penicillamine's activity against RNA neurotropic viruses, because it is effective against the auto-immune disease, rheumatoid arthritis, and because both viruses and autoimmunity have been implicated in multiple sclerosis." | 3.66 | Pilot study of d-penicillamine, vitamins and minerals in multiple sclerosis. ( Alba, A; Berger, AR; Rudez, A; Seelig, MS; Tarlau, M, 1978) |
| "It has been suggested that lead may be a cause of multiple sclerosis, but confirmation of this hypothesis is difficult to obtain as lead is so widely present both in the environment and in many human tissues." | 3.65 | Lead and multiple sclerosis. ( , 1976) |
| "The diagnosis of MS preceded that of Wilson's disease and was relatively mild in course." | 2.82 | Rare co-occurrence of multiple sclerosis and Wilson's disease - case report. ( Despotov, K; Klivényi, P; Nagy, I; Pálvölgyi, A; Rajda, C; Vécsei, L, 2022) |
| "Multiple sclerosis is a chronic inflammatory disease of the CNS leading to focal destruction of myelin, still the earliest changes that lead to lesion formation are not known." | 1.32 | Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. ( Graumann, U; Reynolds, R; Schaeren-Wiemers, N; Steck, AJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Despotov, K | 1 |
| Klivényi, P | 1 |
| Nagy, I | 1 |
| Pálvölgyi, A | 1 |
| Vécsei, L | 1 |
| Rajda, C | 1 |
| Graumann, U | 1 |
| Reynolds, R | 1 |
| Steck, AJ | 1 |
| Schaeren-Wiemers, N | 1 |
| Norga, K | 1 |
| Paemen, L | 1 |
| Masure, S | 1 |
| Dillen, C | 1 |
| Heremans, H | 1 |
| Billiau, A | 1 |
| Carton, H | 2 |
| Cuzner, L | 1 |
| Olsson, T | 1 |
| Van Damme, J | 1 |
| Dubois, B | 1 |
| D'Hooghe, MB | 1 |
| De Lepeleire, K | 1 |
| Ketelaer, P | 1 |
| Opdenakker, G | 1 |
| Lodemann, E | 1 |
| Seelig, MS | 1 |
| Alba, A | 1 |
| Berger, AR | 1 |
| Rudez, A | 1 |
| Tarlau, M | 1 |
| Cendrowski, W | 1 |
| Czlonkowska, A | 1 |
1 review available for penicillamine and Multiple Sclerosis
| Article | Year |
|---|---|
Rare co-occurrence of multiple sclerosis and Wilson's disease - case report.
Topics: Copper; Hepatolenticular Degeneration; Humans; Multiple Sclerosis; Penicillamine; Quality of Life | 2022 |
2 trials available for penicillamine and Multiple Sclerosis
| Article | Year |
|---|---|
Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Double-Blind Method; Drug Therapy, Combination; | 1998 |
Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study.
Topics: Adult; Ageusia; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Dyspepsia; Erythema; Fem | 1976 |
5 other studies available for penicillamine and Multiple Sclerosis
| Article | Year |
|---|---|
Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aurora Kinases; Bl | 2003 |
Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine.
Topics: Acute Disease; Animals; Blotting, Northern; Chronic Disease; Collagenases; Encephalomyelitis, Autoim | 1995 |
[D-Penacillamine. From constituent of penicillins to significant drug].
Topics: Arthritis, Rheumatoid; Cystinuria; Hepatitis; Hepatolenticular Degeneration; Humans; Multiple Sclero | 1979 |
Pilot study of d-penicillamine, vitamins and minerals in multiple sclerosis.
Topics: Adult; Autoimmune Diseases; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnesium; Male | 1978 |
Lead and multiple sclerosis.
Topics: Female; Humans; Lead; Lead Poisoning; Male; Multiple Sclerosis; Penicillamine | 1976 |